Investor Home

Corporate Profile

BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival...more >

Stock Quotemore >
BGNE (American Depositary Shares)


 1.05 (3.44%)

09/26/16  2:39 p.m. ET

Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releasesmore >
BeiGene Receives Approval to Initiate Clinical Trials in China with PD-1 Antibody BGB-A317 - September 11, 2016
BEIJING, Sept. 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company fo... Read More
BeiGene Appoints Jane Huang, M.D. as Chief Medical Officer, Hematology - September 6, 2016
WALTHAM, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical com... Read More

Upcoming Events

There are currently no events scheduled.

E-mail Alerts

Sign up to receive e-mail alerts